



(11) **EP 2 970 964 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 15/11 ^(2006.01) **C12N 15/113** ^(2010.01)
A61K 31/7088 ^(2006.01) **A61P 21/00** ^(2006.01)

(48) Corrigendum issued on:
06.03.2019 Bulletin 2019/10

(86) International application number:
PCT/US2014/029766

(45) Date of publication and mention of the grant of the patent:
26.12.2018 Bulletin 2018/52

(87) International publication number:
WO 2014/153240 (25.09.2014 Gazette 2014/39)

(21) Application number: **14723583.2**

(22) Date of filing: **14.03.2014**

(54) **EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY**

VERBESSERTER EXON-SKIPPING-ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON MUSKELDYSTROPHIE

COMPOSITIONS DE SAUTS D'EXON POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(30) Priority: **14.03.2013 US 201361782706 P**

(56) References cited:
WO-A1-2010/048586 WO-A1-2012/029986
US-A1- 2010 168 212

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(60) Divisional application:
18215621.6

(73) Proprietor: **Sarepta Therapeutics, Inc.**
Cambridge, MA 02142 (US)

- **POPPLEWELL L J ET AL: "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials", NEUROMUSCULAR DISORDERS, PERGAMON PRESS, GB, vol. 20, no. 2, 15 January 2010 (2010-01-15), pages 102-110, XP026878306, ISSN: 0960-8966 [retrieved on 2010-01-15]**
- **FOSTER H ET AL: "Genetic therapeutic approaches for Duchenne muscular dystrophy", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 23, no. 7, 30 May 2012 (2012-05-30), pages 676-687, XP002688790, ISSN: 1043-0342, DOI: 10.1089/HUM.2012.099 [retrieved on 2012-05-30]**

(72) Inventors:

- **BESTWICK, Richard, K.**
Bend, OR 97707 (US)
- **FRANK, Diane, Elizabeth**
Seattle, WA 98115 (US)

EP 2 970 964 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- VAN VLIET LAURA ET AL: "Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy", BMC MEDICAL GENETICS, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 1 December 2008 (2008-12-01), page 105, XP021042784, ISSN: 1471-2350, DOI: 10.1186/1471-2350-9-105
- JERRY R. MENDELL ET AL: "Gene therapy for muscular dystrophy: Lessons learned and path forward", NEUROSCIENCE LETTERS, vol. 527, no. 2, 17 May 2012 (2012-05-17), pages 90-99, XP055128775, ISSN: 0304-3940, DOI: 10.1016/j.neulet.2012.04.078
- MOULTON H M ET AL: "Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 1798, no. 12, 17 February 2010 (2010-02-17), pages 2296-2303, XP027430152, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2010.02.012 [retrieved on 2010-02-17]